All Episodes

MPR Weekly Dose Podcast #286 — Alexander Disease Tx; Hyrnuo and Etcamah Approved; Pelacarsen Misses Endpoint; Atogepant Shows Promise in Menstrual Migraines

MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI

MPR Weekly Dose Podcast #285 — Mounjaro Approval Expanded; Updated RSV Pediatric Recs; Remibrutinib Shows Promise for Relapsing MS; Boxed Warning Added to Injectafer PI

Navigating the New mRNA Flu Shot: A Discussion With Dr William Schaffner

MPR Weekly Dose Podcast #283 — mRNA Influenza Vaccine; Pluvicto for PSMA+ mHSPC; Mucinex 12HR Approved; Narcolepsy Tx Approved; Peanut Allergy Treatment Fast Tracked

MPR Weekly Dose Podcast #282 — OTC Acetaminophen/Naproxen; Novel ADHD Tx; COVID-19 PEP; Contraceptive Patch; Furosemide Autoinjector for Edema

MPR Weekly Dose Podcast #281 — Kalshi Start Clinical Trial Predictions; Positive Results for Retatrutide; Jideytro Approved; Smart Toilet Launches; Daraxonrasib NDA Accepted

MPR Weekly Dose Podcast #280 — Cyclospora Outbreak Latest; Hypercholesterolemia Tx Approved; New Lecanemab SC Regimen; Oral Sleep Apnea Tx; Revtorpyk Approved for Breast Cancer

MPR Weekly Dose Podcast #279 — Trutakna Approved; Xtoro and Amerithroid Now Available; Casgevy Approval Expanded; Lupus Tx Granted Breakthrough Designation

MPR Weekly Dose Podcast #278 — Once-Weekly HIV Tx; Hympavzi Approval Expanded; Orforglipron Assessed in Menopause; Warning Label for Weight Loss Tx

MPR Weekly Dose Podcast #277 — Treatment Approved for cUTI; COVID-19 Postexposure Prophylaxis; Eye Drops Fail to Meet Endpoint; Afrezza Indication Expanded; Obefazimod UC Trial Results

MPR Daily Dose Podcast #276 — Retatrutide Shows Significant Weight Loss; Hepcludex Approved; Acne Gel for OTC Use; Linzess Indication Expanded; Camizestrant Review Extended

MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked

MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative

MPR Weekly Dose Podcast #273 — Gene Therapy Approved for Rare Hearing Loss; Pattern Hair Loss Tx Shows Growth; Brestri for Asthma; CRISPR gene for HAE; Novel Obesity Tx

MPR Weekly Dose Podcast #272 — Idvynso Approved for HIV; Expanded Indication for Dupixent; Novel Tx Shows Promise for Pancreatic CA; Oral Semaglutide for Adolescents; GLP-1 Potential Knee OA Tx

MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion

MPR Weekly Dose Podcast #270 — High Dose Wegovy; Durvalumab Combo for Unresectable HCC; Generic Dapagliflozin; Yuviwel Now Available for Achondroplasia

MPR Weekly Dose Podcast #269 — Lifyorli, Avlayah Approved; Lyme Disease Vaccine Trial Results; Once-Weekly Basal Insulin Approved for T2DM

MPR Weekly Dose Podcast #268 — Childhood Immunization Schedule Changes Blocked; High Dose Wegovy Gets Green Light; Hidradenitis Suppurativa Tx Indication Expanded; Triple Therapy Show Significant Weight Loss

MPR Weekly Dose Podcast #267 — Sotyktu, Leucovorin Gain Approval; Follicular Lymphoma Treatment Withdrawn; FDA to Review Potential Hypertension Drug

MPR Weekly Dose Podcast #266 — Generic Flovent HFA; Achondroplasia Tx Gains Approval; Dupixent Approved for Allergic Fungal Rhinosinusitis; Swallowable Gastric Balloon

MPR Weekly Dose Podcast #265 — Wakix Approval Expanded; Psoriasis, Weight-Loss Combo Tx; Psilocybin Shows Promise in TRD; Remibrutinib for Chronic Inducible Urticaria; Injectable Regimen Benefits HIV Treatment Adherence

MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment

MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review

MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold

MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression

MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News' Annika Urban

MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome

MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review

MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval

MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen

MPR News Weekly Dose #255 — Fluoride Supplements Restricted; AAP Leucovorin Statement; At-Home Ultrasound; Kygevvi Approved; Gazyva Lupus Trial Results

MPR Weekly Dose #254 — Tranexamic Acid Label Change; New Tezspire Approval; Psychedelic Gains Breakthrough; Oral Semaglutide for MACE Reduction; Gazyva Approved for Lupus

MPR Weekly Dose Podcast #253 — Bipolar I Treatment; Blood-Based Test for Alzheimer Disease; UC Tx Approved for Pediatrics; Rinvoq Expanded; Oral Glucagon-Like Peptide-1

MPR Weekly Dose Podcast #252 — CDC Approves New Immunization Sched; Novel Furosemide Delivery Device; New IPF Treatment Approved; Libtayo approved for CSCC; Breakthrough Therapy for influenza

MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked

MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda

MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn

MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated

MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated

MPR Weekly Dose Podcast #247 — AAP Release Pediatric Immunization Schedule; Blood Pressure MGMT Guideline; Wegovy Approved for Noncirrhotic MASH; New Fibromyalgia Tx; Investigational Sickle Cell Tx Fails to Meet Endpoint

MPR Weekly Dose Podcast #246 — Device Cleared for Sleep Apnea; Skysona Safety Update; Non-Cystic Fibrosis Bronchiectasis Tx; Animal-Derived Thyroid Meds Safety Update; Synagis Discontinued

MPR Weekly Dose Podcast #245 — Label Change for Opioids; Results From Weight-Loss Pill Trial; Ajovy Approved for Some Peds; Ixchiq Vaccine Restrictions Lifted; Modeyso Approved for Rare Brain Tumor

MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib

MPR Weekly Dose Podcast #243 — Sarepta Pauses Elevidys Shipments; Advisory Committee Votes Against PTSD Tx; Rapiblyk Now Available; Pill for Sleep Apnea; JUUL Cigs Authorized

MPR Weekly Dose #242 — New indication for Kerendia; investigational Tx shows promise for hypertension; Novolog biosimilar; trial results for hormone-free contraceptive; new prefilled Shringrix syringe

MPR Weekly Dose Podcast #241 — RFK Jr Sued Over Vaccine Policy Changes; Hereditary Angioedema Tx Approved; New OTC Blood Pressure Monitor; Kisunla Dosing Regime; REMS removed for ERA meds

MPR Weekly Dose Podcast #240 — Wristband to Improve Tremors; Weight Loss Risk With ADHD Meds; REMS Eliminated for CAR T-Cell Immunotherapies; Zegfrovy Approved; New CDC Advisory Committee Has First Meeting

MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results

MPR Weekly Dose Podcast #238 — Nucala New Indication; FDA To Make COVID-19 Vaccines Harder to Obtain; Pruritus Reported With Allergy Med Discontinuation; Oral Antibiotic for cUTIs; Investigational Celiac Tx Fast Tracked

MPR Weekly Dose Podcast #237 — At-Home Cervical CA Screening; FDA Assess Removing Fluoride Products; Chikungunya Vaccination Pause; SC Inj. for Migraine Tx; Gene Therapy for Hunter Syndrome

MPR Daily Dose Podcast #236 — Needle-Free Epinephrine for Peds; Oral Semaglutide for Weight Mgmt; Wearable Defibrillator; Hypertension Tx Approved; Stelara Biosimilar

MPR Weekly Dose Podcast #235 — Rinvoq Approval Expanded; Wegovy Telehealth Link-Up; Epidermolysis Bullosa Wound Healing Tx; Imaavy Approved for gMG; Nasal Powder to Treat Migraines

MPR Weekly Dose Podcast #234 — Alert for Compounded Finasteride; Cytisinicline Improves Smoking Cessation; GERD Tx Shows Promise; ACIP Makes New Vaccine Recs

MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury

MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk

MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC

MPR Weekly Dose Podcast #230 — New Antibiotic for uUTIs; Treatment Approved for Advanced Neuroendocrine Tumors; New Rosacea Tx Option; Tremfya Gains Crohn Disease Indication; Dept. of HHS Cuts 10,000 Jobs

MPR Weekly Dose Podcast #229 — Flu Vaccine Recommendations; Patient Dies Following Gene Therapy; Chikungungya Vaccine; Zunveyl Available; REMS Removed for Tryvio

MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments

MPR Weekly Dose Podcast #227 — Labeling Changes for Testosterone Products; Food Allergy Treatments Compared; FDA Approves Stroke Tx; COVID-19, Flu Vaccine Effectiveness for Recent Season; Neffy 1mg Approved

MPR Weekly Dose Podcast #226 — REMS Removed for Schizophrenia Tx; New Copper Intrauterine Device; Wegovy, Ozempic Supply Update; Lumbar Disc Disease Tx Fast Tracked; Tourette Syndrome Shows Promise

MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed

MPR Weekly Dose Podcast #224 — Strategy for High-Threshold Peanut Allergy; Emblaveo Approved for Complicated Infections; New Formulation of Evrysdi; FDA Fast Tracks Designations Investigational Agents for Alzheimer Disease and Cannabis Use Disorder.

MPR Weekly Dose 223 — Diabetes Devices Alert Warning; Continuous Apomorphine Device Approved for Parkinson Disease; Symbravo Approved; New Pain Tx; Propranolol May Cut Stroke Risk

MPR Weekly Dose 222 — Ozempic expanded approval; MS treatment gets Boxed Warning; Monotherapy approval for Spravato; Alzheimer Tx maintenance regimen; Enhertu new Breast CA indication

MPR Weekly Dose Podcast #221 — OTC Phenylephrine Removal; Schizophrenia Drug Efficacy Data; FDA Vote on Sotagliflozin; IV Ibuprofen vs Ketorolac; Semaglutide Improves Liver Fibrosis

Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies

MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared

MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple's Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis

MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine

MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard

MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk Reduction Trial

MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD

MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication

MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval

MPR Weekly Dose Podcast #211 — Duvyzat Available; Device to Treat Nasal Congestion; Pediatric Tx to Delay Diabetes; Soliris Biosimilar; First Orally-Disintegrating Contraceptive

MPR Weekly Dose Podcast #210 — Clonazepam ODT Recall; Parkinson Disease Tx Gets Fast Tracked; Pancreatic CA Vaccine; Voquenzna New Approval; Endari Generic

MPR Weekly Dose Podcast #209 — Atopic Dermatitis Topical; Wet AMD Implant Available Again; Neurostimulation Device for RA; FDA Denies Weekly Insulin; Smarthphone Therapy for Fibromyalgia

MPR Weekly Dose Podcast #208 — Ohtuvayre Approved; Generic Victoza; DMD Gene Therapy Expanded; Treatment for Pediatric Narcolepsy; OTC Video Game for ADHD

MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded

MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx

MPR Weekly Dose Podcast #205 — Entresto Generics; mRNA-Based RSV Vaccine; Doxycycline PEP for STI Prevention; FDA Vote on MDMA Therapy; Rinvoq Indication Expanded

MPR Weekly Dose 204 — Novel ADHD Extended-Release Tx; Soliris Biosimilar Approved; Depression, Insomnia Tx; FDA Vote on Colorectal CA Test; Mistrust in the FDA

MPR Weekly Dose Podcast 203 — Urinary Incontinence Device; Autoinjector Warning for MS Tx; COVID-19 Preexposure Prophylaxis; Elyea Biosimilars; Lung Cancer Treatment Approved

MPR Weekly Dose 202 — Unreliable COVID-19 Tests; Insulin Pump App Update; Noninvasive Colorectal CA Test; Self-Collection HPV Screening Option; Drug Threats to the US

Drug Shortage Crisis: An interview with Dr. Michael Ganio

Psilocybin for Depression: An interview with Dr. Charles Raison

MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test

MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection

MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning

MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System

MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results

MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva

MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled

MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning

MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter

MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete's Foot Spray Recalled

MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops

MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler

MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended

MPR Weekly Dose 186 — Diabetes Tx Suicidal Ideation Link Examined; Topical Molluscum Contagiosum Tx; Superpotent IV Bags Recalled; Syphilis Treatment Update; Menstrual Blood to Measure HbA1c

MPR Weekly Dose 185 — Best Diets for 2024; Counterfeit Ozempic; Myasthenia Gravis Tx Approved; Herpes False Positive Test Results; Promethazine Hydrochloride Safety Concerns

MPR Weekly Dose 184 — Gel Approved for EB Wounds; 21-Valent Pneumococcal Vaccine; Prescription Game Therapy for ADHD; HIV-Protecting Vaginal Insert; Multiple Food Allergy Drug

MPR Weekly Dose 183 — Updated Diabetes Guidelines; Novel Blood Collection Device; Postpartum Depression Tx; Male Birth Control Study; Approval Sought for Psychoactive Drug

MPR Weekly Dose Podcast #182 — Novel Weight Loss Tx; Safety Risks for Compounded Semaglutide; Fabhalta Approved for PNH; At-Home Insemination Kit; Sleep Apnea Device Cleared

MPR Weekly Dose Podcast #181 — Serious Reactions to Seizure Treatments; Desmoid Tumor Tx; Secondary CAR T-Cell Malignancies; Immunosuppressive Recall; CPAP Machine Issues

MPR Weekly Dose Podcast #180 — Chikungunya Vaccine; Amazon FDA Warning; At-Home STD Test; Lymphoma Drug Withdrawn; Antimicrobial Catheter Lock Solution for CRBSI

MPR Weekly Dose Podcast #179 — Weight Management Tx; Levemir Discontinued; Renal Denervation System Approved; Gene Therapy Fasted Tracked; Hidden Drugs in Glucose Supplement

MPR Weekly Dose Podcast #178 — FDA Flags Eye Drops; Ped Alert for COVID-19 Vaccine; Novel Heartburn Tx; Biosimilar to Stelara Approved; Anti-Fentanyl Monoclonal Antibody

MPR Weekly Dose Podcast 177 — Penbraya Approved; COVID-19 Therapy Shelf-Life Extended; New Formulation for IBD Tx; Self-Admin FluMist; Nonopioid Combo for Postop Pain

MPR Weekly Dose 176 — Novel MDD Tx; Panel Votes Against ALS Therapy; Preservation-Free Iyuzeh; RSV Vaccine Recommended for During Pregnancy; Investigative Tx Shows Promise in FCS

MPR Weekly Dose 175 — Xacduro Now Available; Epinephrine Application Denied; Flu Vaccine Efficacy; New Dosing Regimen for Talicia; Change to Generic Tacrolimus

MPR Weekly Dose 174 — Updated COVID-19 Vaccines; Px Drop for Dry Eye Disease; Crohn Disease Tx Trial; Lotronex Update; FDA Cracks Down on Unapproved Eye Products

MPR Weekly Dose Podcast #173 — Talking vaccines with Dr. Abdul-Mutakabbir

MPR Weekly Dose 171 — Vaccine Guidance for Flu Season; PrEP Recommendation; Maternal RSV Vaccine; Latest on Updated COVID Vaccine; CHAPLE Disease Tx Approved

MPR Weekly Dose 170 — Warning Alert for Tests; Arexy Available for Older Adults; Sohonos and Hezato Kit Approved; Statement on GLP-1 Use Before Endoscopy

MPR Weekly Dose 169 — New Postpartum Depression Tx; Generic Naloxone Spray; Weight Management Drug Shows Heart Benefits; CDC Recommends RSV Vaccine; SAD Tx

MPR Weekly Dose 168 — Prescription stimulant shortage; Electronic transfer of controlled substances; Oral contraceptive recall; Ebola vaccine; OTC opioid overdose approval

MPR Weekly Dose 167 — Molluscum contagiosum Tx approved; Xdemvy and Balfaxar approved; Weight loss drug in short supply; Cervical pessary assessed for reducing preterm birth

MPR Weekly Dose 166 — Potential Alzheimer drug may slow disease; RSV Tx for neonates, toddlers; Veklury and Brenzavvy approvals expanded; Blood test false negatives

MPR Weekly Dose 165 — OTC Birth Control Pill; Heart Tx Gains Expanded Approval; Gavreto Indication Withdrawn; Albuterol Inhaler Recall; Paclitaxel-Coated Device Analysis

MPR Weekly Dose 164 — Approvals for Alopecia, Generalized Myasthenia Gravis, and Type 1 Diabetes; Colonoscopy Prep; FDA Deny Application for Pre-Cirrhotic Fibrosis Tx

MPR Weekly Dose 163 — COVID-19 Vaccine Authorization Revoked; Injectafer Approved; Lumryz Single Dose for Narcolepsy; Vowst for C. Difficile; Approval for CMV Disease Prevention

MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx

MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall

MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child's Smart Thermometer Recalled

MPR Weekly Dose 159 — OTC Birth Control Pill Switch; First Tx for Agitation Associated With Dementia; Fabry Disease Treatment; Farxiga Approval Expanded; Contaminated COVID-19 Tests

MPR Weekly Dose 158 — Early Alzheimer Treatment; First RSV Vaccine; Narcolepsy Tx; Toilet Seat That Monitors Health; FDA Ammonia Warning

MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert

MPR Weekly Dose 156 — Bivalent COVID-19 Vaccines; Vote on Agitation With Alzheimer Dementia Tx; Descheduled Drug; Migraine Tx Expansion; Restless Legs Syndrome Device

MPR Weekly Dose 155 — Knee Shock Absorber; Opioid Label Updates; Imbruvica Indications Withdrawn; Patch for Excessive Sweating; Polyclonal Tx for Flu

MPR Weekly Dose 154 — Novel COVID-19 Tx Granted EUA; Makena Withdrawn; Infant Supine Sleep System; Padcev Plus Keytruda Approved; Opioid Mail-Back Envelopes, Respiratory Depression Detection Device

MPR Weekly Dose 153 — Diabetes Drugs Discontinued; Trial Results for Schizophrenia Tx; Intranasal Spray Assessed for SAD; High-concentration Humira biosimilar; Inspire Therapy Indication Expanded

MPR Weekly Dose 152 — Booster Dose Authorized for Under 5s; Rapid STI Test; Rett Syndrome and Migraine Tx Approved; Panel Takes Vote for Polivy Combo

MPR Weekly Dose 151 — Liver Injury Decline Tied to FDA Rule; Alzheimer Disease Tx Update; Bempedoic Acid in MACE; Blood Test Cleared for TBI Assessment; Mammography Regulatory Update.

MPR Weekly Dose 150 — Kevzara, Skyclarys Approved; At-Home Combo COVID and Flu Test; Drug-Resistant Shigellosis on Rise; FDA Restrictions on Xylazine-Containing Products

MPR Weekly Dose 149 — Post-Exposure Molnupiravir Study; Filspari Approved; Treatment for Geographic Atrophy Secondary to AMD Approved; Personalized Melanoma Vaccine; RSV Maternal Vaccine

MPR Weekly Dose 148 — OTC Narcan; Fecal Microbiota Available; Azithromycin for Postpartum Sepsis; Cibinqo Expanded Approval; Delgocitinib for Hand Eczema

MPR Weekly Dose 147 — Adlyxin Availability; Zuranolone Priority Review; Recall of Hypothyroidism Treatment; Weight Loss Supplement Warning; First ROP Treatment

MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy

MPR Weekly Dose 145 — COVID-19 Vaccine Investigation; HIV Vaccine Lacks Efficacy; Sepsis Diagnostic Test; RSV-Associated Disease Vaccine; Combo Tx Reduces CA Recurrence

MPR Weekly Dose 144 — New Alzheimer disease Tx; Asthma rescue therapy; NERD Tx shows promise; Leukemia drug to be withdrawn; Adacel approved for during pregnancy

MPR Weekly Dose 143 — Pharmacists can dispense abortion pill; MDMA trial meets endpoints; HIV meds to be discontinued; Obesity Tx approved for children; 2023 best diets rankings

MPR Weekly Dose 142 — Interview with US News managing health editor, Gretel Schueller

MPR Weekly Dose 141 — Guidance for Influenza Treatment; Panel Vote on Omecamtiv Mecarbil; Tecentriq Approval; Flu and COVID Combo Vax; Certain COVD Tests Recalled

MPR Weekly Dose 140 — COVID-19 Vaccines; Narcan for OTC; Diabetes Tx in Peds; Major Depressive Disorder Therapy Fast Tracked; Tecentriq Indication Withdrawn

MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy

MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor

MPR Weekly Dose 137 — USPSTF Hormone Recommendations; Semaglutide in Obese Teens; Maternal RSV Vaccine Candidate; Antipsychotic REMS Update; Omburtamab Panel Vote

MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil

MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended

MPR Weekly Dose 134 — Vaccine Boosters Authorized; Wearable Furosemide System Approved; Molnupiravir Data; Pertussis Vaccine; FDA Apomorphine Device Update

MPR Weekly Dose 133 — ALS Treatment Approval; Evusheld Update; At-Home Epilepsy Diagnosis; Clopidogrel, Atenolol Recall; Laser Therapy for Fibromyalgia

MPR Weekly Dose 132 — Social Media Warning; Cisplatin-Associated Ototoxicity Tx; New Cerebral Adrenoleukodystrophy Tx; MRI Contrast Agent; Generic Tazorac

MPR Weekly Dose 131 — Approvals in Plaque Psoriasis, Hepatorenal Syndrome and Neutropenia; Priority Review for Rett Syndrome Therapy; Multivitamins Assessed in Cognition

MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved

MPR Weekly Dose 129 — Omicron-Adapted Booster Dose; Influenza Season Guidance; Nirmatrelvir Efficacy; DEA Warn Over "Rainbow Fentanyl"; Chronic Idiopathic Constipation Tx

MPR Weekly Dose 128 — USPSTF Statin Recommendations; At-Home Visual Test; Novel MDD Treatment; Novavax Authorized in Adolescents; FDA Fecal Microbiota Transplant Alert

MPR Weekly Dose 127 — Novavax Booster; OTC Hearing Aids; Combo Prostate Cancer Tx; First Gene Therapy for Beta-Thalassemia; Repeat At-Home COVID-19 Testing Needed

MPR Weekly Dose 126 — Change to Monkeypox Vaccine Supply; Myfembree Indication Expanded; Amazon Among Companies to Receive FDA Warning; Impurity in Diabetes Tx

MPR Weekly Dose 125 — Device Cleared to Treat C-Section Pain; Plaque Psoriasis Cream; Contrast Agent Shortage Addressed; Lucentis Biosimilar Approved; OTC Laxative Recall Expanded

MPR Weekly Dose 124 — Novavax Vaccine Gains EUA; Comirnaty Adolescent Approval; OTC Switch for Contraceptive; Nasal Spray Available OTC; Dupilumab for Pediatric EoE

MPR Weekly Dose MPR 123 — Paxlovid Prescribing; Evusheld Dosing Updates; New Abuse-Deterrent Opioid; Lecanemab Priority Review; Morphine Tablet Recall

MPR Weekly Dose MPR 122 — Nasal Spray for Allergic Rhinitis; Qsymia Approval Expanded; Monkeypox Vaccine; Antibodies Shelf Life Extended; FDA Ban JUUL Products

MPR Weekly Dose MPR 121 — New Treatment for Crohn Disease; USPSTF Recommendations on Vitamins for CVD, CA Prevention; Panel Vote on Alzheimer Tx; Phexxi Analysis; Vaxneuvance Approved for Pediatrics

MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis

MPR Weekly Dose MPR 119 — FDA Panel Votes on Novavax; MMR Vaccination; Dupixent Approval Expanded; Investigative COVID-19 Treatments

MPR Weekly Dose 118 — Ukoniq Approval Withdrawn; Rescue Inhaler to Be Reviewed; Dupilumab Priority Review; Kymriah Update; Novel Postpartum Depression Tx Shows Promise

MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert

MPR Weekly Dose 116 — First-in-Class T2D Treatment; FDA Decline Fluvoxamine; Booster Doses for Children; COVID-19, Influenza, and RSV Test; Wearable Furosemide Delivery System

MPR Weekly Dose 115 — Janus Kinase Inhibitor Approved for COVID-19; Varenicline Supply; Janssen Vaccine Limits Set; Test Safety Alert; Potential Hemodialysis Chemical Exposure

MPR Weekly Dose 114 - USPSTF Aspirin Recommendations; COVID-19 treatment expansion; Accupril Recall; Counterfeit HIV Meds; White House Plan to Tackle Overdose Epidemic

MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated

MPR Weekly Dose 112 - Second COVID-19 Booster Dose Authorized; Sotrovimab Use Limited; Oral COVID-19 Tx; PreHevbrio Hep B Vaccination; Thyroid Dysfunction Alert Following ICM

MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted

MPR Weekly Dose #110: Interview With Dr Tobias Janowitz

MPR Weekly Dose 109 - Purdue Overdose Treatment Approved; ACIP Immunization Schedules; FDA Provide List of COVID-19 Tests; Urticaria Trial Stopped; First Condom for Anal Intercourse.

MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine

MPR Weekly Dose 107 - Millions of Molnupiravir Courses Delivered; Guidance on Nonopioid Analgesic Development; Enteral Feeding Tube Warning; Enjaymo Approved; Mecarbil Under Review for HFrEF

MPR Weekly Dose 106 - FDA Approves COVID-19 Vaccine; EUA Submission for Kids Under 5; COVID Tests Recalled; Vupanorsen Development Ends; Cabenuva Approval Expanded

MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved

MPR Weekly Dose 104 - Two New Atopic Dermatitis Therapies; Counterfeit HIV; Indications Withdrawn for Zydelig; CDC Pediatric Influenza Vaccine Study Results; COVID Test Warning

MPR Weekly Dose 103 - Novel treatment for insomnia; Magnesium health claim; Dental decay and transmucosal med; Vaccine and menstrual cycle findings; Best diets for 2022

MPR Weekly Dose 102 - COVID-19 vaccine contraindication; Final results for COVID-19 antiviral; Entadfi approved; CAR T-cell REMS change; New approval for psoriatic arthritis

MPR Weekly Dose 101 - COVID-19: Pre-exposure prophylaxis approved; Omicron vaccine protection; Antibody authorized for kids; Heterolous boosting assessed; Veklury recall

MPR Weekly Dose 100 - Paxlovid EUA submission; Drugs linked to orthostatic hypotension; Besremi approved; Pill for remote endoscopy; Largest psilocybin trial to date

MPR Weekly Dose 99 - Oral COVID-19 candidate reduces risk of death; aromatherapy sprays recalled; Presbyopia Tx; Naloxone alternative; Migraine drug head-to-head study

MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn

MPR Weekly Dose 97 - 'Mix and Match' Boosters Authorized; Biosimilar to Humira; Nasal Spray for Dry Eye Disease; Novel Pain Treatment; Opioid Overdose Treatment

MPR Weekly Dose 96 - Updated Aspirin Recommendations; Needle-Free Warning; Isotretinoin REMS program; Pediatric Athymia Tx; EU Request for Molnupiravir; Advisory Panel Votes on Moderna Booster Shot

MPR Weekly Dose 95 - Interview with Dr Preeti Malani, Chief Health Officer and Professor of Medicine in the Division of Infectious Diseases at the University of Michigan

MPR Weekly Dose 94 - COVID Vaccine Booster Doses; Pediatric Vaccine Trial; Parental Vaccine Hesitancy; Remdesivir and Hospitalization Risk; Atopic Dermatitis Treatment

MPR Weekly Dose 93 - Mandatory Opioid Prescriber Education; Rise in Delta-8 THC Products; Brukinsa and Exkivity Approved; Warning Letters for Supplement Companies

MPR Weekly Dose 92 - AAP Vaccination Guidance; Moderna Booster; JAK Inhibitor Warnings; New Migraine Treatment Nasal Spray; Hold Placed on Phenylketonuria

MPR Weekly Dose 91 - First Full COVID-19 Vaccine Approval; Pfizer Submit for Third Dose; AAP Advises on Off-Label Vaccinations; COVID Antibody Tx; Moderna BLA Submission

MPR Weekly Dose 90 - COVID-19 Vaccine Booster Dose; Vaccine for Tick-Borne Encephalitis; Jardiance Approval; FDA Wristband Warning; Jemperli Accelerated Approval

MPR Weekly Dose 89 - COVID Vaccine Booster Dose; Vaccines Recommended in Pregnancy; Post-Vaccine Myocarditis Study; Moderna Efficacy at 6 Months; Pompe Disease Tx; FDA Denies Roxadustat

MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn

MPR Weekly Dose 87 - Statin contraindication change; Vaccine for streptococcus pneumoniae; Plaque psoriasis cream; Therapy fast tracked for Parkinson disease; Bylvay approved

MPR Weekly Dose Podcast Episode 86

MPR Weekly Dose 85 - Chantix recalled; Kimyrsa for ABSSSI; Aduhelm label update; Blood lead test recall; Keytruda changes

MPR Weekly Dose 84 - Emergency Use for COVID-19 treatment; Fact sheet update for vaccines; Rylaze approved; Expanded approval for Solosec; NDA submitted for HIV-1 treatment

MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer

MPR Weekly Dose 82 - A regenerative skin therapy; Novavax vaccine shows promise; Mastocytosis treatment; Potential new depression treatment; And an FDA warning for hand sanitizers.

MPR Weekly Dose 81 - A first therapy to target underlying process of Alzheimer disease; Moderna requests EUA; And a list of new approvals in a variety of therapeutic categories

MPR Weekly Dose 80 - Migraine prevention treatment; Pediatric combo vaccine; Schizophrenia, Bipolar I approval; AI-based Autism diagnostic

MPR Weekly Dose 79 - COVID-19: vaccine storage, efficacy updates; Gene therapy Fast Tracked; Vitiligo cream trial results; Aspirin dosage compared in ASCVD

MPR Weekly Dose 78 - Vaccine authorized for adolescents; Postoperative pain Tx approval; Insulin products recalled; Treatment Fast Tracked for facioscapulohumeral muscular dystrophy

MPR Weekly Dose 77 - Updated mask guidance; Janssen vaccine resumption; Steroid therapy in COVID-19; Novel MDD gains Priority Review; Scabies treatment; Stroke rehabilitation device

MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment

MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system

MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine

MPR Weekly Dose #73: Interview with Dr Joshua Barocas

MPR Weekly Dose 72 - Real world vaccine effectiveness; Two-dose completion data; Moderana pediatric trial; Results from tocilizumab plus remdesivir trial; Kimyrsa approved.

MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions

MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables

MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens.

MPR Weekly Dose #68 - Remdesivir compounding; Emergency Use Authorizations; Sleep apnea device; New Botox approval

MPR Weekly Dose #67 - Efficacy data for AstraZeneca, J&J and Novovax vaccines; Approvals in analgesia and influenza.

MPR Weekly Dose 66 - The Moderna vaccine's efficacy against new variants; Merck ends development of new vaccines; Antiviral treatment combos show promise; New lupus nephritis treatment

MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling

MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled

MPR weekly dose #63 - COVID-19 vaccine admin scheduling and production updates; A diagnostic test that is giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021.

MPR Weekly Dose #62 - Major vaccine developments; FDA authorizes rapid at-home COVID test; New findings for glucosamine supplementation; And a novel budesonide oral suspension gets Priority Review

MPR Weekly Dose #61 - Sitagliptin findings in pediatrics; Obesity treatment gains expanded approval; The FDA issue a CRL; And a new transdermal contraceptive

MPR Weekly Dose #60 - The FDA stand by remdesivir; Who should get the vaccine first? Xolair and Hetlioz gain expanded approvals; And a novel neuroblastoma treatment

MPR Weekly Dose #59 - The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test; Keytruda gains expanded approval; and more

MPR Weekly Dose #58 - Major developments in COVID vaccine and antibody treatments; Also an FDA Advisory Committee vote on what would be the first Alzheimer drug in decades.

MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news

MPR Weekly Dose Episode #56 - Antibody responses; Convalescent plasma; Nasal spray for diabetic gastroparesis; Colorectal cancer screening recommendations; New dry eye treatment; And movie trivia!

MPR Weekly Dose Podcast Episode 55

Weekly Dose #54 - Vaccine trial halted; Hyperimmune trial begins; IV tramadol rejected; FDA votes on schizophrenia, bipolar Tx; And a first in Ebola treatment

Weekly Dose #53 - Encouraging news on antibody therapies; EUA guidelines for potential vaccines; Remdesivir distribution; The HIV drug that failed to have an impact; And the preterm birth treatment the FDA want withdrawn from the market.

Weekly Dose #52 – New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval.

MPR Weekly Dose Podcast Episode 51

Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning

Weekly Dose #49 - ACIP vaccine guidelines; Convalescent plasma; 15 minute test; Plant warning; Intrauterine device; Hydrochlorothiazide

Pneumonia Associated COVID-19; Inaccurate Tests; Neck Gaiters; Drug Applications Halted; Narcan Update

Weekly Dose #47: Remdesiver news; New opioid, SMA treatments; Sublingual epinephrine; Alzheimer treatment

COVID Vaccine Developments; Long-Term Facility Study; Cannabidiol; New Depression Treatment; Peanut Allergy Rejection

MPR Weekly Dose Podcast Episode 45

MPR Weekly Dose Podcast Episode 44

MPR Weekly Dose Podcast Episode 43

MPR Weekly Dose Podcast Episode 42

MPR Weekly Dose Podcast Episode 41

MPR Weekly Dose Podcast Episode 40

MPR Weekly Dose Podcast Episode 39

MPR Weekly Dose Podcast Episode 38

MPR Weekly Dose Podcast Episode 37

MPR Weekly Dose Podcast Episode 36

MPR Weekly Dose Podcast Episode 35

MPR Weekly Dose Podcast Episode 34

MPR Weekly Dose Podcast Episode 33

MPR Weekly Dose Podcast Episode 32

MPR Weekly Dose Podcast Episode 31

MPR Weekly Dose Podcast Episode 30

MPR Weekly Dose Podcast Episode 29

MPR Weekly Dose Podcast Episode 28

MPR Weekly Dose Podcast Episode 27

MPR Weekly Dose Podcast Episode 26

MPR Weekly Dose Podcast Episode 25

MPR Weekly Dose Podcast Episode 24

MPR Weekly Dose Podcast Episode 23

MPR Weekly Dose Podcast Episode 22

MPR Weekly Dose Podcast Episode 21

MPR Weekly Dose Podcast Episode 20

MPR Weekly Dose Podcast Episode 19

MPR Weekly Dose Podcast Episode 18

MPR Weekly Dose Podcast Episode 17

MPR Weekly Dose Podcast Episode 16

MPR Weekly Dose Podcast Episode 15

MPR Weekly Dose Podcast: Episode 14

MPR Weekly Dose Podcast Episode 13

MPR Weekly Dose Podcast Episode 12

MPR Weekly Dose Podcast: Episode 11

MPR Weekly Dose Podcast Episode 10

MPR Weekly Dose Podcast Episode 9

MPR Weekly Dose Podcast Episode 8

MPR Weekly Dose Podcast: Episode 7

MPR Weekly Dose Podcast: Episode 6

MPR Weekly Dose Podcast: Episode 5

MPR Weekly Dose Podcast: Episode 3

MPR Weekly Dose Podcast: Episode 2

MPR Weekly Dose Podcast: Episode 1